Inj ustekinumab-stba, 1 mg
Products billed under this code include Steqeyma.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Steqeyma.
Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Steqeyma | Celltrion USA, Inc. | 72606-0027-01 | 45 | $130.05 |
| Steqeyma | Celltrion USA, Inc. | 72606-0028-01 | 90 | $260.10 |
| Steqeyma | Celltrion USA, Inc. | 72606-0029-01 | 130 | $375.70 |
| Steqeyma | Celltrion USA, INC. | 72606-0060-01 | 45 | $130.05 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $2.89 | −$0.185 | 1 MG | Inj ustekinumab-stba, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $3.075 | +$0.001 | 1 MG | Inj ustekinumab-stba, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $3.074 | −$8.779 | 1 MG | Inj ustekinumab-stba, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $11.853 | −$0.789 | 1 MG | Inj ustekinumab-stba, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $12.642 | – | 1 MG | Inj ustekinumab-stba, 1 mg | v1, posted September 8, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.